C225 WITH CHEMORADIATION FOR NSCLC

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine the feasibility of concurrent Cetuximab and chemoradiation as measured by safety and compliance. 1) Estimate the treatment response rate of patients on the study regimen; 2) Estimate overall survival of patients on the study regimen; 3) Estimate the time to disease progression of patients on the study regimen; and 4) Investigate associates between EGFR expression and toxicity, response, overall survival and progression.